Background on risk-sharing and insight into risk-sharing agreements from a payer’s and manufacturer’s perspective.
Outcome-Based Contracting Acceptance Grows in market with the concept of taking on financial risk on complex contracts as a result of market pressure combined with more familiarity. Outcome-based contracts between pharma companies and health insurers are becoming increasingly popular. In 2016, Novartis, Amgen, and Sanofi publicized risk-sharing, value-based, outcomes-based, or pay-for-performance deals, all of which vary […]
Managed care pharmacy survey findings 2016 Managed Healthcare Executive September 26, 2016 To identify the top managed care pharmacy challenges and what your peers are doing about them, Managed Healthcare Executive, in partnership with Access Market Intelligence and the National Institute of Collaborative Healthcare, conducted its first-ever pharmacy survey during the second quarter of 2016. […]
Future of Specialty Pharmacy – Recent events involving Valeant and Philidor have caused an uproar in the marketplace along with the Turing Pharmaceutical (and generics) mess around pricing. Now the NY Times casts the light on Horizon and Linden illustrating the bad without much good around stakeholder relationships that pharma firms have utilized. Due to the evolution […]
“Cyramza, approved earlier this year for stomach cancer, is a key product in Lilly’s oncology portfolio,” said John Santilli, of Access Market Intelligence, which provides market intelligence to the pharmaceutical and healthcare industries. “With the colorectal cancer market becoming increasingly crowded, Lilly will need to review the pricing strategy for Cyramza to make sure the drug remains competitive […]